Top

Published in:

02-09-2022 | Colorectal Cancer | Original Article

Histopathological Predictors of Microsatellite Instability in Colorectal Cancer—a Tertiary Care Center Experience

Authors: Singh Aminder, Jindal Saveena, Soni Ankita, Kaur Harpreet, Jain Kunal, Narang Vikram, Grover Sumit, Garg Bhavna, Kaur Ramneek

Published in: Indian Journal of Surgical Oncology | Issue 1/2023

Abstract

Microsatellite instability (MSI) has a therapeutic and prognostic implication in colorectal carcinomas (CRCs). It can be detected either by immunohistochemistry (IHC) or molecular studies. In developing countries, a significant proportion of the patients experience financial constraints limiting the utilization of healthcare facilities. We aimed to identify the possible clinicopathological variables which can be used as predictors of microsatellite instability in such patients. CRC cases received for MSI detection by IHC (for 1 and 1/2 years) were included. A panel of four IHC markers (anti-MLH1, anti-PMS2, anti-MSH2, and anti-MSH6) was used. Confirmation by the molecular study was recommended in all the IHC-proven MSI cases. Various clinicopathological parameters were evaluated as predictors of MSI. Microsatellite instability was detected in 40.6% (30/74) cases with MLH1 and PMS2 dual loss in 27% cases, MSH2 and MSH6 dual loss in 6.8%, loss of all four MMR proteins in 2.7%, and isolated PMS2 loss in 4.1%. MSI-H expression was shown by 36.5% cases with only 4.1% cases showing MSI-L expression. The age cut-off value to differentiate both the study groups (MSI vs MSS) was 63 years with a sensitivity of 47.7% and specificity of 86.7%. ROC curve showed an area under the curve of 0.65 (95% CI, 0.515–0.776; p-value = 0.03). On univariate analysis, age < 63 years, colon site, and absence of nodal metastasis were significantly higher in the MSI group. However, on multivariate analysis, only the age < 63 years was found to be significantly higher in the MSI group. Confirmation was molecular study could only be obtained in 12 cases and was completely concordant with MSI detection by IHC. MSI detection can be performed either by IHC or by molecular study. In this study, no histological parameter appeared to be the independent predictor of MSI status. The age < 63 years might predict the microsatellite instability, yet larger studies are needed for its validation. Thus, we recommend that IHC testing should be performed in all CRC cases.

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA: Cancer J Clin 55(2):74–108CrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer J Clin 61(2):69–90CrossRef

National Cancer Registry Programme, Indian Council of Medical Research: three year report of population based cancer registries 2012‑2016. Available from: https://www.ncdirindia.org/All_Reports/Report_2020/default.aspx

Sinicrope FA, Sargent DJ (2012) Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 18(6):1506–1512. https://doi.org/10.1158/1078-0432.CCR-11-1469CrossRefPubMedPubMedCentral

Elsaleh H, Iacopetta B (2001) Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 1(2):104–109. https://doi.org/10.3816/CCC.2001.n.010CrossRefPubMed

Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126(2):394–401. https://doi.org/10.1053/j.gastro.2003.12.023CrossRefPubMed

Elsaleh H, Shannon B, Iacopetta B (2001) Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy. Gastroenterology 120(5):1309–1310. https://doi.org/10.1053/gast.2001.23646CrossRefPubMed

Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, Gerald WL, Ellis NA (2005) Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 29(1):96–104. https://doi.org/10.1097/01.pas.0000146009.85309.3bCrossRefPubMed

Nayak SS, Roy P, Arora N, Arun I, Roy MK, Banerjee S, Mallick I, Mallath MK (2018) Prevalence estimation of microsatellite instability in colorectal cancers using tissue microarray based methods - a tertiary care center experience. Indian J Pathol Microbiol 61(4):520–525. https://doi.org/10.4103/IJPM.IJPM_430_17CrossRefPubMed

10.

Kakar S, Aksoy S, Burgart LJ, Smyrk TC (2004) Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 17(6):696–700. https://doi.org/10.1038/modpathol.3800093CrossRefPubMed

11.

Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257PubMed

12.

Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, Young J, Buchanan D, Walsh MD, Le Marchand L, Burnett T, Newcomb PA, Grady WM, Haile RW, Casey G, Plummer SJ, Krumroy LA, Baron JA, Thibodeau SN (2011) Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the colon cancer family registry. J Mol Diagn 13(3):271–281. https://doi.org/10.1016/j.jmoldx.2010.12.004CrossRefPubMedPubMedCentral

13.

Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, Zeng Z, Rosenberg S, Shia J, Barany F, Paty PB (2010) Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. Ann Surg Oncol 17(12):3370–3378. https://doi.org/10.1245/s10434-010-1147-4CrossRefPubMedPubMedCentral

14.

Kim YH, Min BH, Kim SJ, Choi HK, Kim KM, Chun HK, Lee H, Kim JY, Chang DK, Son HJ, Rhee PL, Rhee JC, Kim JJ (2010) Difference between proximal and distal microsatellite-unstable sporadic colorectal cancers: analysis of clinicopathological and molecular features and prognoses. Ann Surg Oncol 17(5):1435–1441. https://doi.org/10.1245/s10434-009-0888-4CrossRefPubMed

15.

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268. https://doi.org/10.1093/jnci/djh034CrossRefPubMed

16.

Pandey V, Prabhu JS, Payal K, Rajan V, Deepak C, Barde S, Jagannath P, Borges A, Sridhar TS (2007) Assessment of microsatellite instability in colorectal carcinoma at an Indian center. Int J Colorectal Dis 22(7):777–782. https://doi.org/10.1007/s00384-006-0241-3CrossRefPubMed

17.

Singh P, Sharma K, Tewari R, Misra V, Dwivedi M, Misra SP (2015) Clinico – histopathological features of colonic adenocarcinoma in young (<50 years) patients with special reference to microsatellite instability status. Indian J Med Res Pharm Sci 2:9–18

18.

Kanth VV, Bhalsing S, Sasikala M, Rao GV, Pradeep R, Avanthi US, Reddy DN (2014) Microsatellite instability and promoter hypermethylation in colorectal cancer in India. Tumour Biol 35(5):4347–4355. https://doi.org/10.1007/s13277-013-1570-9CrossRefPubMed

19.

Rajkumar T, Soumittra N, Pandey D, Nancy KN, Mahajan V, Majhi U (2004) Mutation analysis of hMSH2 and hMLH1 in colorectal cancer patients in India. Genet Test 8(2):157–162. https://doi.org/10.1089/gte.2004.8.157CrossRefPubMed

20.

Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L, Gill AJ (2014) BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol 27(5):644–650. https://doi.org/10.1038/modpathol.2013.200CrossRefPubMed

21.

Bacher JW, Flanagan LA, Smalley RL, Nassif NA, Burgart LJ, Halberg RB, Megid WM, Thibodeau SN (2004) Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers 20(4–5):237–250. https://doi.org/10.1155/2004/136734CrossRefPubMedPubMedCentral

22.

McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN (2015) Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 137(2):306–310CrossRefPubMed

23.

Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 10(4):293–300. https://doi.org/10.2353/jmoldx.2008.080031CrossRefPubMedPubMedCentral

24.

Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M, Thibodeau SN (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20(4):1043–1048. https://doi.org/10.1200/JCO.2002.20.4.1043CrossRefPubMed

25.

Long Q, Peng Y, Tang Z, Wu C (2014) Role of endometrial cancer abnormal MMR protein in screening lynch-syndrome families. Int J Clin Exp Pathol 7(10):7297–7303PubMedPubMedCentral

26.

Chen W, Frankel WL (2019) A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol 32:1–15. https://doi.org/10.1038/s41379-018-0136-1CrossRefPubMed

27.

Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30(8):1232–1243. https://doi.org/10.1093/annonc/mdz116CrossRefPubMed

28.

Kawakami H, Zaanan A, Sinicrope FA (2015) Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol 6(6):676–684. https://doi.org/10.3978/j.issn.2078-6891.2015.065CrossRefPubMedPubMedCentral

Title: Histopathological Predictors of Microsatellite Instability in Colorectal Cancer—a Tertiary Care Center Experience
Authors: Singh Aminder
Jindal Saveena
Soni Ankita
Kaur Harpreet
Jain Kunal
Narang Vikram
Grover Sumit
Garg Bhavna
Kaur Ramneek
Publication date: 02-09-2022
Publisher: Springer India
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Indian Journal of Surgical Oncology / Issue 1/2023
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-022-01633-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Histopathological Predictors of Microsatellite Instability in Colorectal Cancer—a Tertiary Care Center Experience

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Fungating and Ulcerating Breast Cancer: Wound Closure Algorithm, Complications, and Survival Trends

A Retrospective Cohort Study of Gastrosplenic Fistula Secondary to Malignant Etiology: Single-Centre Experience of 5 Cases

Papillary Thyroid Carcinoma Arising from Thyroglossal Cyst—an Institutional Experience over a Decade

LICAP Versus TDAP for the Reconstruction of Partial Breast Defects

Malignant Adenomyoepithelial Tumour of the Breast — a Rare Diagnosis — Case Report

Synchronous Metastatic Follicular Carcinoma and BRAF Mutated Papillary Carcinoma Thyroid—a Rare Occurrence